SCHEMBL5357946

SCHEMBL5357946

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1ccc(Br)o1)C(=O)N2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 2/20 0.64
SRC P12931 7/20 0.55
KDR P35968 5/20 0.54
CDK2 P24941 2/20 0.54
POLB P06746 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
G6PD P11413 1/20 0.52
NTRK1 P04629 1/20 0.50
FCER2 P06734 1/20 0.50
SYK P43405 1/20 0.50
NTRK3 Q16288 1/20 0.50
NTRK2 Q16620 1/20 0.50
LCK P06239 4/20 0.47
FYN P06241 4/20 0.47
YES1 P07947 4/20 0.47
FGFR1 P11362 4/20 0.47
PDGFRB P09619 3/20 0.47
AURKA O14965 1/20 0.45
RPS6KA3 P51812 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5358670 0.87 MEN1 (0.60) RETSRCKDRCDK2POLB
SCHEMBL5358453 0.84 SRC (0.53) SRCKDRCDK2POLBMEN1
SCHEMBL5368250 0.84 SRC (0.55) RETSRCKDRCDK2POLB
SCHEMBL7139469 0.84 SRC (0.52) SRCKDRCDK2POLBMEN1
SCHEMBL5373623 0.82 SRC (0.55) SRCKDRCDK2POLBMEN1
SCHEMBL5361707 0.81 ALDH1A1 (0.67) SRCKDRCDK2NTRK1FCER2
SCHEMBL5368553 0.79 KDR (0.54) SRCKDRCDK2POLBMEN1
SCHEMBL5369843 0.79 SRC (0.59) SRCKDRCDK2NTRK1FCER2
SCHEMBL7140809 0.79 SRC (0.54) RETSRCKDRCDK2NTRK1
SCHEMBL5363032 0.79 SRC (0.54) SRCKDRCDK2POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK RET 283/4885SRC 189/4885KDR 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.